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Chronic elevation of the sympathetic nervous system has been identiﬁed as a major con-
tributor to the complex pathophysiology of hypertension, states of volume overload – such
as heart failure – and progressive kidney disease. It is also a strong determinant for clin-
ical outcome. This review focuses on the central role of the kidneys in the pathogenesis
of sympathetic hyperactivity. As a consequence, renal denervation may be an attractive
option to treat sympathetic hyperactivity.The review will also focus on ﬁrst results and the
still remaining questions of this new treatment option.
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INTRODUCTION
Convincing evidence reveals chronic elevation of the sympathetic
nervous system (SNS) as a major contributor to the complex
pathophysiology of (essential) hypertension, states of volume
overload – heart failure for example – and progressive kidney
disease (Klein et al., 2003a; DiBona, 2004).
Sympathetic renal denervation offers an attractive option to
treat these disease states. The concept of renal denervation is
not new. Complex, non-selective, procedures were effectively used
as a treatment of severe hypertension before antihypertensive
drugs became generally available (Peet, 1948). These treatments
were effective, but associated with a high rate of peri-operative
morbidity, mortality, and long-term complications (Krum et al.,
2009). Nevertheless catheter based sympathetic renal denerva-
tion is an upcoming and exciting therapeutic tool. This less
invasive approach disrupts the renal efferent and afferent sym-
pathetic nerves in the adventitia of the renal arteries, using
relative low-power and precisely focused radiofrequency bursts
of ≈8W.
This short review focuses on two subjects. Firstly the central
role of the kidneys in the pathogenesis of sympathetic hyperac-
tivity will be highlighted. Secondly this review focuses on the ﬁrst
results of the studies on renal denervation and the still remaining
questions on renal denervation.
THE CENTRAL ROLE OF THE KIDNEY IN THE PATHOGENESIS
OF CHRONIC ELEVATION OF THE SNS
CLINICAL STUDIES ON SYMPATHETIC ACTIVATION
Kim et al. (1972) provided indirect evidence for the existence
of sympathetic activation in patients with end-stage kidney dis-
ease (ESKD) and hypertension. They showed that hyperten-
sion in ESKD is caused by an increased peripheral resistance.
Nephrectomy resulted in a signiﬁcant reduction of blood pressure
(BP) and peripheral resistance. In contrast, in normotensive ESKD
patients nephrectomy had no effect on BP, peripheral resistance,
and cardiac output (Kim et al., 1972).
The ﬁrst direct clinical evidence pointing to a role for activa-
tion of the SNS in diseased kidneys came from Converse et al.
(1992). They showed that sympathetic nerve activity assessed by
muscle sympathetic nerve activity (MSNA; microneurographic
technique to assess true sympathetic activity) is increased in
patients with chronic kidney disease (CKD). In bilateral nephrec-
tomized patients, MSNA was comparable to controls (Converse
et al., 1992).
These clinical ﬁndings show that activationof the SNS in severe-
or end-stage kidney failure is causedbydiseasedkidneys.A recently
published study by Grassi et al. (2011) provides further evidence
for a crucial involvement of the SNS in patients with a moderately
impaired kidney function. In these patients and in control patients
with hypertension and a normal kidney function,MSNA is signif-
icantly and inversely correlated with eGFR (Grassi et al., 2011).
In patients with polycystic kidney disease, MSNA is also increased
regardless of kidney function (Klein et al., 2001). The presence of
cysts results in areas of kidney ischemia (Klein et al., 2001). Fur-
thermore in young subjects with mild or borderline hypertension,
MSNA is already increased. The magnitude of hypertension par-
allels the severity of sympathetic activation as assessed by MSNA
(Grassi et al., 1998). These studies indicate that sympathetic activa-
tion is most likely an early event in the pathophysiology of chronic
kidney failure.
KIDNEY ISCHEMIA
Kidney ischemia is an essential step in the development of activa-
tion of the SNS and renin angiotensin system (RAS; Blankestijn
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et al., 2000; Blankestijn, 2004; Joles and Koomans, 2004; Koomans
et al., 2004; Neumann et al., 2004; Siddiqi et al., 2009). During
kidney ischemia adenosine is released as a result of decreased oxy-
gen supply (Katholi et al., 1984). Direct infusion of adenosine
into the renal artery in conscious dogs produces hypertension by
activating the SNS (Katholi et al., 1984). The effects of intrarenal
adenosine on BP are most likely related to increased afferent renal
nerve activity and can be prevented by renal denervation (Katholi
et al., 1984).
Whether the effects of kidney injury on the activity of the SNS
in the kidney are direct or mediated via angiotensin II (AngII) is
unclear (Siddiqi et al., 2009). Increases in renal sympathetic nerve
activity and activity of the RAS both inﬂuence renal- and vascu-
lar function. Besides the systems interact directly and indirectly
(DiBona, 2000a, 2001). Direct intrarenal interactions take by spe-
ciﬁc innervation, indirect intrarenal interactions occurs via AngII.
Interactions can also be extrarenal; for instance in the central ner-
vous system (CNS) where renal sympathetic nerve activity and
the baroreﬂex control are modulated by changes in activity of the
RAS (DiBona, 2000a, 2001). For example: renovascular hyperten-
sion – a classical example of kidney ischemia – is characterized
by hyperactivity of the SNS as assessed by MSNA. Treatment by
angioplasty decreasesMSNA,plasma renin activity, and the plasma
concentration of AngII (Miyajima et al., 1991).
Even a minute injury by injection of phenol into one kidney,
without affecting kidney function, stimulates central sympathetic
activation (Ye et al., 1998), stimulates both afferent and efferent
renal sympathetic activity, and induces hypertension in rats (Ye
et al., 1997,2002). TheBP-elevating effect of phenol canbe reduced
or prevented by renal denervation (Ye et al., 1997, 2002). Also par-
tial renal ablation by arterial ligation and induction of renal artery
stenosis causes hypertension (Faber and Brody, 1985; Campese
et al., 1995). Renal efferent and afferent innervation plays a cru-
cial role; the effects of these abnormalities are largely prevented by
renal denervation.
KIDNEYS AS A GENERATOR AND RECIPIENT OF SYMPATHETIC
ACTIVITY
Besides being a generator of sympathetic activity, the kidney also
acts as recipient of efferent signals. Renal efferent nerves are com-
prised of functionally speciﬁc groups of ﬁbers which separately
innervate and control the function of juxtaglomerular granular
cells, tubules, and vessels. Responses of the kidney to efferent activ-
ity occur differentially in relation to graded intensity of renal nerve
stimulation (DiBona, 2000b). This arrangement permits maximal
ﬂexibility.
Increased renal sympathetic activity leads to a cascade of
actions: renal blood ﬂow and glomerular ﬁltration rate decreases
by renal vasoconstriction. Secondly by stimulating the release of
renin by the juxtaglomerular cells, AngII is produced. This is fur-
ther ampliﬁed by direct activation of the RAS by kidney injury.
Increases in renal sympathetic nerve activity also directly increase
renal tubular sodium reabsorption.
Angiotensin II directly causes vasoconstriction, has trophic
effects, stimulates the SNS vasomotor center in the brainstem, and
plays an important role in the water and chloride reabsorption in
the proximal tubule (Reid, 1992).
FIGURE 1 | Schematic representation of the kidney involvement in the
pathogenesis of sympathetic hyperactivity. Minimal kidney damage, not
necessarily affecting kidney function, results in area(s) of ischemia. This
results in increased afferent nerve activity and increased levels of AngII in
plasma and CNS. Increased central sympathetic outﬂow affects many
organs also including the cardiovascular system. In addition, AngII may
enhance sympathetic activity on the peripheral level.
Angiotensin II and the renal nerves interact. An example of the
interaction between AngII and renal innervation is given by Hen-
del and Collister (2006); a long-term low-dose AngII infusion in
rats leads to a gradual increase in BP (Hendel and Collister, 2006).
This effect could partially be prevented by renal denervation (Hen-
del and Collister, 2006). Furthermore the intravenous infusion of
AngII in humans stimulates sympathetic activity as assessed by
MSNA (Matsukawa et al., 1991).
Besides its peripheral actions, experimental research suggests
that AngII contributes to the regulation of arterial pressure
and intravascular volume through actions on several brain sites
(DiBona, 1999, 2001). A hormonal-sympathetic reﬂex model for
the long-term control of arterial pressure has been proposed
(Brooks and Osborn, 1995; Brooks, 1997; Osborn, 1997). Indeed
acute increases in circulating AngII concentration affect the SNS
through actions on the brain, sympathetic ganglia, and sympa-
thetic nerve endings (Reid, 1992). However the mechanism of the
effect of chronic increases of AngII on sympathetic nerve activ-
ity is unclear (DiBona, 2000a, 2001). The proposed mechanism is
schematically shown in Figure 1.
Aldosterone is another important hormone in the regulation
of BP. The production of aldosterone in the adrenal glands is
stimulated by AngII. In the kidneys it increases tubular sodium
reabsorption, leading to an increase in renal sodium retention and
a decrease in urinary sodium excretion. Aldosterone is a steroid
that can easily enter the brain (Hendler and Livingston, 1978; De
Nicola et al., 1981; Birmingham et al., 1984; Funder and Myles,
1996; Uhr et al., 2002). Acting via mineralocorticoid receptors,
aldosterone increases sympathetic nerve activity by up regulating
the brain RAS components and induction of oxidative stress in the
hypothalamus (Zhang et al., 2008).
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The diseased kidneys are important in the pathogenesis of
sympathetic hyperactivity, however several other factors may be
involved as well, including renalase (Boomsma and Tipton, 2007;
Desir, 2011), NO-related mechanisms (Krukoff, 1999; Mallamaci
et al., 2004), tonic chemoreﬂex activation (Hering et al., 2007),
obesity (da Silva et al., 2009), and insulin (Lambert et al., 2010).
Whether these mechanisms directly affect the CNS, exhibit their
effect s via the kidneys or both is unclear.
TREATMENT OF SYMPATHETIC ACTIVATION
There is abundant evidence that sympathetic hyperactivity inde-
pendent of BP is detrimental to health. With the pathophysiology
in mind, pharmacological inhibition of the RAS is a logical step
in the treatment of disease states in which sympathetic activation
plays a crucial role. Treatment with ACE inhibitors (ACEi) and
AngII receptor blockers (ARB) in patients with CKD resulted in
a BP and MSNA lowering effect. However MSNA was not com-
pletely normalized (Klein et al., 2003b; Neumann et al., 2007).
Moreover SNS as assessed by MSNA is associated with the com-
posite of all causemortality and non-fatal cardiovascular events in
CKD patients despite treatment with ACEi or ARB (Penne et al.,
2009).
The increased risk on mortality and cardiovascular events in
CKD is the result of the involvement of the sympathetic activation
in the pathogenesis of organ damage. Sympathetic activation has
differentmodes of action on several pathways like structural effects
on the heart and vascular system. In human studies, indexes of left
ventricular hypertrophy (LVH) correlate with plasma noradren-
aline values (Marcus et al., 1994) and cardiac noradrenaline spill
over (Kelm et al., 1996). Also in essential hypertension, the occur-
rence of LVH is associated with an increase inMSNA (Greenwood
et al., 2001).
The incomplete normalization of sympathetic activation in
pharmacologic treatment and its associated risks, asks for new
treatment options. Catheter based renal denervation may provide
an important new treatment option.
THE FIRST RESULTS AND REMAINING QUESTIONS
BROAD EFFECT RANGE AND NON-RESPONDERS
Presently three studies on the effect of renal denervation on BP are
available. All suggest a substantial effect (Krum et al., 2009; Esler
et al., 2010; SymplicityHTN-1 Investigators, 2011). In the Simplic-
ity HTN-2 trial (Esler et al., 2010) 106 patients with hypertension
resistant to therapy were randomly allocated to treatment or con-
trol group. In patients treated with renal denervation, ofﬁce-based
BP declined with 32/12mmHg 6months after renal denervation,
compared with no change in controls. However a broad range of
effect was observed evidenced by a SD of 23/11mmHg. More-
over in 10% of patients systolic BP did not decrease and were
classiﬁed as non-responders. The presence of non-responders and
the broad effect range has several possible explanations. Firstly it
could be due to a failure of the intervention; perhaps the treat-
ment was unsuccessful because the nerves were only partially
destroyed. Another explanation is that the cardiovascular system
did not respond to the decrease of the sympathetic activity. Years
of hypertension made the vasculature too rigid and diseased, so
that it is unable to dilate and lower vasculature resistance after
the procedure. On the other hand, it is also possible that in the
particular patient the renal nerves were not involved in the patho-
physiology and other BP-elevating mechanisms are operational.
Although, secondary forms of hypertension are among exclu-
sion criteria, a secondary cause of hypertension was not actively
ruled out in all patients. It is possible that among the group of
non-responders, secondary forms of hypertension like hyperal-
dosteronism (a hypervolemic state with low sympathetic activity)
and other forms of endocrine hypertension, are common. It seems
unlikely that this procedure is effective in these patients. There-
fore, it is recommended to actively exclude (treatable) secondary
causes of hypertension, before performing renal denervation.
At this moment we can not distinguish between the possible
explanations for treatment failure in a particular patient. As a
consequence it is not possible yet to identify patients most likely to
beneﬁt from renal denervation. It is reasonable to hypothesize that
patients with signs of kidney injury – for example an increased
renin activity or decreased kidney perfusion/oxygenation – and
patients with signs of activation of the SNS – for example a non-
dipping pattern of the 24-h ambulatory BP – will probably beneﬁt
most from renal denervation.
The HTN-1 Investigators (Symplicity HTN-1 Investigators,
2011) only identiﬁed a higher baseline systolic BP and the use of
central sympatholytic agents as signiﬁcant independent predictors
of response (Symplicity HTN-1 Investigators, 2011).
Theoretically, an elegantmanner to identify responders is a run-
in periodwith administration of clonidine, a centrally acting alpha
agonist, which reduces central sympathetic outﬂow. Patients who
react beneﬁcially might be good candidates for renal denervation
(Katholi et al.,2010).Of note is that in theHTN-2 trial almost halve
of the participants used central acting sympathicolytic agents.
MONITORING OF THE EFFECT OF RENAL DENERVATION
Another important limitationof renal denervation is that presently
there is no easy variable available to monitor the intervention. If
one accepts the pathophysiologic model,MSNA would be an ideal
method. It offers the opportunity to determine efferent sympa-
thetic activity, and thus potentially makes it possible to learn more
on the pathophysiology of non- and poor responders. Unfortu-
nately MSNA is invasive and time consuming, so it is not suitable
for daily practice.
In the proof-of-principle study (Krum et al., 2009) release
of noradrenaline from the renal sympathetic nerves was mea-
sured in 10 patients with the isotope dilution renal noradrenaline
spillover method. In these patients renal noradrenaline spillover
was reduced with an average of 47% (Krum et al., 2009). This
method requires the administration of radioactive isotopes and is
not suitable to apply in daily patient care.
Schlaich et al. (2009) studied the effect of renal denerva-
tion, in one individual, on renal plasma ﬂow, left ventricu-
lar mass, and MSNA. Again a pronounced BP-lowering effect
was found: BP was reduced from 161/107mmHg at baseline
to 127/87mmHg 12months after renal denervation. Moreover,
renin activity reduced by 50%; renal plasma ﬂow increased with
almost 56%; left ventricular mass decreased with almost 9%; and
MSNA substantially reduced (Schlaich et al., 2009). These are
intriguing results that can only be explained by accepting the
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pathophysiologic model presented in Figure 1. It gives strong
support for a central role of the kidneys in the pathogenesis of
hypertension and that renal denervation destructs the afferent
renal nerves.
PHYSIOLOGY OF THE BP-LOWERING EFFECT OF RENAL DENERVATION
The BP-lowering effect of renal denervation increases in time,
6months after treatment the effect seems to be maximal. A clear
explanation for the increasing effect is not available. The effects of
renal denervation occur by functional changes (rapid effects) and
structural changes such as reversal of vascular hypertrophy. These
structural changes may take some time to occur.
It is reasonable to hypothesize that the BP-lowering effect is
due to both an altered water/sodium handling by the kidneys and
a decrease in peripheral vascular resistance.
It is suggested by Liu and Cogan (1988) that for optimal water
and chloride reabsorption in the proximal tubule,AngII, and renal
innervation interact. After renal denervation, the effect of AngII to
increase water and chloride reabsorption was decreased by ≈75%
(Liu andCogan,1988). This indicates that themajority of the effect
of AngII is dependent on intact innervation and that an impor-
tant action of AngII is to facilitate the release of noradrenaline in
the presynaptic site of the sympathetic nerve terminals (DiBona,
2000a).
Renal denervation also signiﬁcantly increased basal renal blood
ﬂow, improved dynamic autoregulation of renal blood ﬂow, and
increased renal blood ﬂow variability in rats with congestive heart
failure and rats with spontaneous hypertension, compared with
controls (DiBona and Sawin, 2004). Schlaich et al. (2009) also
found an increase in renal plasma ﬂow from 719 to 1126mL/min
after renal denervation in one single patient.
RENOPROTECTIVE EFFECT OF RENAL DENERVATION
Conclusions from animal studies suggest that renal denervation
has a renoprotective effect independent of lowering BP. In Dahl
salt-sensitive hypertensive rats, renal denervation leads to local
renal sympatho-inhibition in absence of a BP-lowering effect. This
results in decreased urinary albumin excretion, reduced glomeru-
losclerosis and podocyte injury (Nagasu et al., 2010). Inﬂamma-
tion and oxidative stress are risk factors for progressive renal
dysfunction (Modlinger et al., 2004). Veelken et al. (2008) sug-
gested that renal denervation protects kidney function through an
anti-inﬂammatory effect (Veelken et al., 2008). They reported that
denervation signiﬁcantly reduced albuminuria,mesangiolysis, for-
mation of micro-aneurysms,deposition of glomerular collagen IV,
and expression of transforming growth factor-β in experimental
glomerulonephritis in rats (Veelken et al., 2008).
Also the reduction of BP alone would be expected to be
beneﬁcial to impaired kidneys and slow down kidney failure
progression. An analysis of long-term clinical trials such as the
Modiﬁcation of Diet in Renal Disease Trial (MDRD), demon-
strated that a decrease in BP results in preservation of kidney
function (Peterson et al., 1995; Lazarus et al., 1997).
In the observational study, kidney function remained stable
during the ﬁrst year after renal denervation. However 2 years
post-procedure data on eGFR are available of 10 patients,
in them eGFR changed on average by −16.0mL/min/1.73m2
(Symplicity HTN-1 Investigators, 2011). The authors explained
the drop in eGFR in ﬁve patients by adding spironolactone or
another diuretic after the ﬁrst year of follow-up. In patients
without newly added spironolactone or another diuretic, eGFR
changed with 7.8mL/min/1.73m2. Since these data are observa-
tional, without a control group, it is questionable whether the
decrease in eGFR is due to renal denervation or is the effect of
years of hypertension. The effect of renal denervation on kidney
function is not completely clear yet.
KIDNEY INDEPENDENT SYMPATHETIC ACTIVITY
A substantial part of overactivity of the SNS in hypertension is
kidney dependent. There is much evidence that kidney ischemia
is of crucial importance in this pathway. It is unknown whether
increased efferent renal nerve activity also exists as a primary
abnormality. It is possible that in certain genetic forms or stress
related hypertension this could be the case. However, this is difﬁ-
cult to determine. Since in renal denervation both the afferent, as
the efferent renal nerves will be interrupted, it potentially will also
be successful in these patients.
POSSIBLE INDICATIONS FOR RENAL DENERVATION
It seems worth exploring the role of renal denervation in other
patient groups characterized by sympathetic activation like milder
forms of hypertension, sleep apnea, heart failure, metabolic syn-
drome, obesity, chronic kidney failure and dialysis, hepatorenal
syndrome, and cardiorenal syndrome. A pilot study shows us
that renal denervation improves glucose metabolism and insulin
sensitivity in addition to the BP-lowering effect. Even in the sub-
group of patients with diagnosed diabetes mellitus at study entry,
renal denervation signiﬁcantly reduced fasting glucose and insulin
sensitivity (Mahfoud et al., 2011).
CONCLUSION
There is convincing evidence that kidney injury can cause sympa-
thetic overactivity. This sympathetic activation is detrimental to
health and reduction may improve clinical outcome. Renal den-
ervation offers new opportunities, not only in the treatment of
patients, but also in the effort to better understand the pathophys-
iology in various disease conditions characterized by sympathetic
overactivity.
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